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Background
B7-H3 positive tumors, including osteosarcoma, neuro-
blastoma, and high grade glioma, cause significant morbid-
ity and mortality despite aggressive multimodality
treatments. Current B7-H3-targeted immune-therapies
take advantage of the monoclonal antibody 8H9, which is
actively being evaluated in Phase I clinical trials. Engager
T cells, which secrete bispecific engager molecules consist-
ing of single chain variable fragments specific for CD3 and
a tumor antigen, are a new class of antigen-specific
T cells, with the unique ability to redirect bystander
T cells to tumors, amplifying anti-tumor effects. The goal
of this project was to develop B7-H3-specific Engager
T cells, and pre-clinically evaluate their effector function
in vitro and in vivo.
Methods
B7-H3-Engager T cells were generated by transducing
T cells with a retroviral vector encoding a B7-H3-specific
T cell engager and mOrange separated by an internal
ribosomal entry site. B7-H3-Engager T cell effector func-
tion was then evaluated in vitro and in a metastatic
osteosarcoma xenograft model.
Results
Post transduction 70-84% of T cells were positive for
transgene expression. In coculture assay B7-H3-Engager
T cells recognized B7-H3-positive osteosarcoma (LM7),
neuroblastoma (CHLA255), and glioma (U373) cell
lines, as judged by IFN-g secretion, in contrast to
B7-H3-negative tumor cells (HTB-119) (Figure 1). None
of the targets were recognized by T cells secreting enga-
ger molecules specific for an irrelevant antigen (CD19-
Engager T cells). Antigen-dependent recognition was
confirmed in standard cytotoxicity assays (Figure 2). To
assess anti-tumor activity of B7-H3-Engager T cells in
vivo we used a metastatic osteosarcoma xenograft model
that allows for serial bioluminescence imaging of LM7
cells that are genetically modified to express the fire fly
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luciferase gene (LM7-ffLuc). NSG mice were intrave-
nously injected with LM7-ffLuc cells, followed by intra-
venous doses of B7-H3-Engager or control (CD19-
Engager) T cells on days 28 and 35 post LM7-ffLuc
injection. In contrast to control T cells, B7-H3-Engager
T cells had potent anti-osteosarcoma activity (Figure 3)
resulting in a survival advantage of treated mice.
Conclusions
We successfully generated B7-H3-Engager T cells and
demonstrate that these cells recognize and kill B7-H3-posi-
tive tumor cells in an antigen-dependent manner, and have
potent anti-osteosarcoma activity in vivo. Thus, B7-H3-Enga-
ger T cells may present a promising alternative to current
T cell immunotherapy approaches for pediatric solid tumors.
Authors’ details
1Baylor College of Medicine, Houston, TX, USA. 2Baylor College of Medicine,
Center for Cell and Gene Therapy, Department of Pediatrics, Houston, TX,
USA.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P11
Cite this article as: DeRenzo et al.: B7-h3-specific engager T cells for the
immunotherapy of pediatric solid tumors. Journal for ImmunoTherapy of
Cancer 2015 3(Suppl 2):P11.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Figure 3
DeRenzo et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P11
http://www.immunotherapyofcancer.org/content/3/S2/P11
Page 2 of 2
